ANDA 209719, held by Amneal Pharms Co. Solifenacin Succinate.
As of Nov 16, 2026, ANDA 209719 (Solifenacin Succinate), held by Amneal Pharms Co, was first approved by FDA on May 20, 2019, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 20, 2019 | Original application | Approved | None posted |
| Solifenacin Succinate5MG · tablet;oral | Solifenacin Succinate | Discontinued |
| Solifenacin Succinate10MG · tablet;oral | Solifenacin Succinate | Discontinued |
| Jan 4, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 20, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters